Get the Stockscreener App
988.87
2.16%
20.94
After Hours:
986.12
-2.75
-0.28%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $988.87, with a volume of 2.94M.
It is up +2.16% in the last 24 hours and up +5.70% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$967.93
Open:
$971.885
24h Volume:
2.94M
Relative Volume:
0.90
Market Cap:
$881.82B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
35.60
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+13.14%
1M Performance:
+5.70%
6M Performance:
+6.81%
1Y Performance:
+20.38%
1-Day Range:
$964.41
$992.80
1-Week Range:
$850.51
$992.80
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
988.87 | 863.14B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.55 | 539.70B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.11 | 368.19B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
181.24 | 284.52B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.15 | 279.37B | 65.59B | 8.93B | 12.36B | 3.5532 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Foundayo Liver Safety Questions Test Eli Lilly GLP-1 Growth Story - simplywall.st
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence - Benzinga
Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show - 24/7 Wall St.
Are analysts too quick to gloss over Lilly’s liver case? - statnews.com
Eli Lilly Is Maintained at Overweight by Barclays - Moomoo
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,183 to $1,500 - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Icon (ICLR) - The Globe and Mail
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years - investor.lilly.com
Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report - Moomoo
3 Reasons It's Not Too Late to Buy Eli Lilly Stock - The Motley Fool
Eli Lilly and Co To Go Ex-Dividend On May 15th, 2026 With 1.73 USD Dividend Per Share - Moomoo
Is Eli Lilly stock heading for $1,000? - MSN
Eli Lilly Annual Meeting: Directors Win, Governance Changes Fail as Ricks Touts 45% Revenue Jump - Yahoo Finance
Is Eli Lilly Stock Heading for $1,000? - The Motley Fool
Eli Lilly (LLY) Faces Share Decline Amid Liver Failure Report Li - GuruFocus
Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125% - 24/7 Wall St.
FDA Reports Liver Failure in Patient Taking Eli Lilly's Foundayo -- Barrons.com - 富途牛牛
Eli Lilly (LLY) Responds to FDA Adverse Report on Foundayo - GuruFocus
Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months - 24/7 Wall St.
The Most Surprising Thing About Eli Lilly's Impressive Revenue Growth: Just How Much More Potential There Is - AOL.com
Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance - CNBC
Eli Lilly’s (LLY) Weight Loss Pill is Better Than Novo’s, Says Jim Cramer - Insider Monkey
Eli Lilly declares $1.73 per share dividend for second quarter By Investing.com - Investing.com Australia
RBC Capital reiterates Eli Lilly stock rating on liver safety By Investing.com - Investing.com Canada
Why Eli Lilly stock is down 3% today: FDA adverse event data explained - Investing.com
$1.73 a share: Lilly fixes May 15 deadline for June payout - Stock Titan
Is Eli Lilly (LLY) Stock a Buy After the Foundayo FDA Scare? - MEXC
LLY Stock In Spotlight After Wall Street Reaffirms Confidence Post FDA Adverse Event Flag - Stocktwits
Eli Lilly (LLY) Shares Decline Following FDA Adverse Event Repor - GuruFocus
Eli Lilly tells RBC liver case ‘not reasonably related to Foundayo’ - TipRanks
Eli Lilly (LLY) FDA Adverse Event Report Raises Concerns - GuruFocus
Goldman Sachs reiterates Eli Lilly stock buy rating after FDA report - Investing.com Canada
Bernstein upgrades Eli Lilly stock rating amid liver safety concerns - Investing.com
FDA Reports Liver Failure in Patient Taking Lilly's Foundayo -- Barrons.com - 富途牛牛
Wolfe Research reiterates Eli Lilly stock rating after hepatic safety signal - Investing.com Canada
Barclays raises Eli Lilly stock price target on strong tirzepatide sales - Investing.com Canada
Barclays Adjusts Eli Lilly Price Target to $1,400 From $1,350, Maintains Overweight Rating - Moomoo
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Eli Lilly Just Announced Fantastic News for Shareholders - AOL.com
Jim Cramer Praises Eli Lilly’s Performance - Insider Monkey
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more - MSN
Eli Lilly Bets on Gene Therapy With $2.25 Billion Profluent Deal - thelec.net
Eli Lilly and Company $LLY Stake Boosted by W.G. Shaheen & Associates DBA Whitney & Co - MarketBeat
Eli Lilly (LLY) Valuation Check As GLP 1 Growth And Foundayo Approval Lift Guidance - simplywall.st
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling' - Yahoo Finance
Interchange Capital Partners LLC Has $4.62 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Narwhal Capital Management Sells 2,288 Shares of Eli Lilly and Company $LLY - MarketBeat
Keybank National Association OH Sells 4,443 Shares of Eli Lilly and Company $LLY - MarketBeat
Why Eli Lilly (LLY) Stock Is Trading Up Today - Yahoo Finance UK
ruist Reaffirms Buy on Eli Lilly (LLY) After Trial Success - Insider Monkey
Eli Lilly Stock Can Sink, Here Is How - Trefis
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Montarce Lucas | EVP & CFO |
Feb 16 '26 |
Option Exercise |
0.00 |
368 |
0 |
16,418 |
| Custer Kenneth L. | EVP & President, Card Met Hlth |
Feb 16 '26 |
Option Exercise |
0.00 |
207 |
0 |
10,232 |
| Brown Adrienne S | EVP, President LLY Imm |
Feb 16 '26 |
Option Exercise |
0.00 |
391 |
0 |
5,312 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Feb 01 '26 |
Option Exercise |
0.00 |
3,394 |
0 |
29,654 |
| Skovronsky Daniel | EVP, CS&PO & Pres. LRL |
Feb 01 '26 |
Option Exercise |
0.00 |
12,684 |
0 |
150,165 |
| Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD |
Feb 01 '26 |
Option Exercise |
0.00 |
4,108 |
0 |
24,670 |
| Ricks David A | President, Chair, and CEO |
Feb 01 '26 |
Option Exercise |
0.00 |
31,932 |
0 |
547,098 |
| Rau Diogo | EVP & CIDO |
Feb 01 '26 |
Option Exercise |
0.00 |
3,752 |
0 |
23,471 |
| Jonsson Patrik | EVP & President, LLY Int'l |
Feb 01 '26 |
Option Exercise |
0.00 |
3,930 |
0 |
57,581 |
| Hernandez Edgardo | EVP & Pres., Mfg. Operations |
Feb 01 '26 |
Option Exercise |
0.00 |
3,572 |
0 |
43,303 |
0.60%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):